Update on the role of aromatase inhibitors in growth disorders

Hormone Research

Volumn 71, Issue SUPPL. 1, 2009, Pages 57-63

  Dunkel, Leo ^a,b  

^a KUOPIO UNIVERSITY HOSPITAL   (Finland)

^b UNIVERSITY OF EASTERN FINLAND   (Finland)

Author keywords

Androgen; Aromatase inhibitor; Growth; Short stature

Indexed keywords

ADIPONECTIN; ANASTROZOLE; ANDROGEN; AROMATASE INHIBITOR; ESTROGEN; FADROZOLE; FLUDROCORTISONE; FLUTAMIDE; GONADORELIN AGONIST; GONADOTROPIN; GROWTH HORMONE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROCORTISONE; LETROZOLE; PLACEBO; SOMATOMEDIN C; SPIRONOLACTONE; TESTOLACTONE; TESTOSTERONE;

ALBRIGHT SYNDROME; BODY HEIGHT; BONE AGE; BONE DENSITY; BONE DEVELOPMENT; BONE MATURATION; CLINICAL TRIAL; COGNITION; CONFERENCE PAPER; CONGENITAL ADRENAL HYPERPLASIA; DRUG SAFETY; DUAL ENERGY X RAY ABSORPTIOMETRY; ESTROGEN ACTIVITY; ESTROGEN BLOOD LEVEL; ESTROGEN RELEASE; ESTROGEN SYNTHESIS; FEMUR NECK; FERTILITY; FOLLOW UP; GONADOTROPIN BLOOD LEVEL; GROWTH ACCELERATION; GROWTH DISORDER; GROWTH HORMONE DEFICIENCY; HUMAN; INSULIN SENSITIVITY; LUMBAR SPINE; PRIORITY JOURNAL; PUBERTY DISORDERS; SHORT STATURE; SPERMATOZOON COUNT; TESTIS DEVELOPMENT; TESTOSTERONE RELEASE;

AROMATASE INHIBITORS; BODY HEIGHT; BONE DEVELOPMENT; COGNITION; FERTILITY; GROWTH DISORDERS; HEALTH PLANNING GUIDELINES; HUMANS; INSULIN RESISTANCE; LIPIDS; TREATMENT OUTCOME;

EID: 58549105919     PISSN: 03010163     EISSN: None     Source Type: Journal    
DOI: 10.1159/000178040     Document Type: Conference Paper

References (56)

1. Morishima A, Grumbach MM, Simpson ER, Fisher C, Qin K: Aromatase deficiency in male and female siblings caused by a novel mutation and the physiological role of estrogens. J Clin Endocrinol Metab 1995;80:3689-3698.
2. Carani C, Qin K, Simoni M, Faustini-Fustini M, Serpente S, Boyd J, Korach KS, Simpson ER: Effect of testosterone and estradiol in a man with aromatase deficiency. N Engl J Med 1997;337:91-95.
3. Bilezikian JP, Morishima A, Bell J, Grumbach MM: Increased bone mass as a result of estrogen therapy in a man with aromatase deficiency. N Engl J Med 1998;339:599-603.
4. Herrmann BL, Saller B, Janssen OE, Gocke P, Bockisch A, Sperling H, Mann K, Broecker M: Impact of estrogen replacement therapy in a male with congenital aromatase deficiency caused by a novel mutation in the CYP19 gene. J Clin Endocrinol Metab 2002;87:5476-5484.
5. Smith EP, Boyd J, Frank GR, Takahashi H, Cohen RM, Specker B, Williams TC, Lubahn DB, Korach KS: Oestrogen resistance caused by a mutation in the oestrogen-receptor gene in a man. N Engl J Med 1994;331:1056-1061.
6. McTernan PG, Anwar A, Eggo MC, Barnett AH, Stewart PM, Kumar S: Gender differences in the regulation of P450 aromatase expression and activity in human adipose tissue. Int J Obes Relat Metab Disord 2000;24:875-881.
7. Sasano H, Uzuki M, Sawai T, Nagura H, Matsunaga G, Kashimoto O, Harada N: Aromatase in human bone tissue. J Bone Miner Res 1997;12:1416-1423.
8. Aquila S, Sisci D, Gentile M, Middea E, Siciliano L, Ando S: Human ejaculated spermatozoa contain active P450 aromatase. J Clin Endocrinol Metab 2002;87:3385-3390.
9. Nathan L, Shi W, Dinh H, Mukherjee TK, Wang X, Lusis AJ, Chaudhuri G: Testosterone inhibits early atherogenesis by conversion to estradiol: critical role of aromatase. Proc Natl Acad Sci USA 2001;98:3589-3593.
10. Steckelbroeck S, Heidrich DD, Stoffel-Wagner B, Hans VH, Schramm J, Bidlingmaier F, Klingmuller D: Characterization of aromatase cytochrome P450 activity in the human temporal lobe. J Clin Endocrinol Metab 1999;84:2795-2801.
11. Simpson ER, Clyne C, Rubin G, Boon WC, Robertson K, Britt K, Speed C, Jones M: Aromatase - a brief overview. Annu Rev Physiol 2002;64:93-127.
12. Bulun SE, Takayama K, Suzuki T, Sasano H, Yilmaz B, Sebastian S: Organization of the human aromatase p450 (CYP19) gene. Semin Reprod Med 2004;22:5-9.
13. Leschek EW, Jones J, Barnes KM, Hill SC, Cutler GB Jr: Six-year results of spironolactone and testolactone treatment of familial male-limited precocious puberty with addition of deslorelin after central puberty onset. J Clin Endocrinol Metab 1999;84:175-178.
14. Laue L, Kenigsberg D, Pescovitz OH, Hench KD, Barnes KM, Loriaux DL, Cutler GB Jr: Treatment of familial male precocious puberty with spironolactone and testolactone. N Engl J Med 1989;320:496-502.
15. Laue L, Jones J, Barnes KM, Cutler GB Jr: Treatment of familial male precocious puberty with spironolactone, testolactone, and deslorelin. J Clin Endocrinol Metab 1993;76:151-155.
16. Kreher NC, Pescovitz OH, Delameter P, Tiulpakov A, Hochberg Z: Treatment of familial male-limited precocious puberty with bicalutamide and anastrozole. J Pediatr 2006;149:416-420.
17. Feuillan PP, Jones J, Cutler GB Jr: Long-term testolactone therapy for precocious puberty in girls with the McCune-Albright syndrome. J Clin Endocrinol Metab 1993;77:647-651.
18. Feuillan PP, Foster CM, Pescovitz OH, Hench KD, Shawker T, Dwyer A, Malley JD, Barnes K, Loriaux DL, Cutler GB Jr: Treatment of precocious puberty in the McCune-Albright syndrome with the aromatase inhibitor testolactone. N Engl J Med 1986;315:1115-1119.
19. Nunez SB, Calis K, Cutler GB Jr, Jones J, Feuillan PP: Lack of efficacy of fadrozole in treating precocious puberty in girls with the McCune-Albright syndrome. J Clin Endocrinol Metab 2003;88:5730-5733.
20. Feuillan P, Calis K, Hill S, Shawker T, Robey PG, Collins MT: Letrozole treatment of precocious puberty in girls with the McCune-Albright syndrome: a pilot study. J Clin Endocrinol Metab 2007;92:2100-2106.
21. Merke DP, Keil MF, Jones JV, Fields J, Hill S, Cutler GB Jr: Flutamide, testolactone, and reduced hydrocortisone dose maintain normal growth velocity and bone maturation despite elevated androgen levels in children with congenital adrenal hyperplasia. J Clin Endocrinol Metab 2000;85:1114-1120.
22. Laue L, Merke DP, Jones JV, Barnes KM, Hill S, Cutler GB Jr: A preliminary study of flutamide, testolactone, and reduced hydrocortisone dose in the treatment of congenital adrenal hyperplasia. J Clin Endocrinol Metab 1996;81:3535-3539.
23. Wickman S, Sipila I, Ankarberg-Lindgren C, Norjavaara E, Dunkel L: A specific aromatase inhibitor and potential increase in adult height in boys with delayed puberty: a randomised controlled trial. Lancet 2001;357:1743-1748.
24. Hero M, Norjavaara E, Dunkel L: Inhibition of estrogen biosynthesis with a potent aromatase inhibitor increases predicted adult height in boys with idiopathic short stature: a randomized controlled trial. J Clin Endocrinol Metab 2005;90:6396-6402.
25. Karmazin A, Moore WV, Popovic J, Jacobson JD: The effect of letrozole on bone age progression, predicted adult height, and adrenal gland function. J Pediatr Endocrinol Metab 2005;18:285-293.
26. Mauras N, Welch S, Rini A, Klein KO: An open label 12-month pilot trial on the effects of the aromatase inhibitor anastrozole in growth hormone (GH)-treated GH deficient adolescent boys. J Pediatr Endocrinol Metab 2004;17:1597-1606.
27. Mauras N, Gonzalez de Pijem L, Hsiang HY, Desrosiers P, Rapaport R, Schwartz ID, Klein KO, Singh RJ, Miyamoto A, Bishop K: Anastrozole increases predicted adult height of short adolescent males treated with growth hormone: a randomized, placebo-controlled, multicenter trial for one to three years. J Clin Endocrinol Metab 2008;93:823-831.
28. Klein KO, Baron J, Colli MJ, McDonnell DP, Cutler GB Jr: Estrogen levels in childhood determined by an ultrasensitive recombinant cell bioassay. J Clin Invest 1994;94:2475-2480.
29. Klein KO, Martha PM Jr, Blizzard RM, Herbst T, Rogol AD: A longitudinal assessment of hormonal and physical alterations during normal puberty in boys. II. Estrogen levels as determined by an ultrasensitive bioassay. J Clin Endocrinol Metab 1996;81:3203-3207.
30. Wickman S, Dunkel L: Inhibition of P450 aromatase enhances gonadotropin secretion in early and midpubertal boys: evidence for a pituitary site of action of endogenous E. J Clin Endocrinol Metab 2001;86:4887-4894.
31. Metzger DL, Kerrigan JR: Estrogen receptor blockade with tamoxifen diminishes growth hormone secretion in boys: evidence for a stimulatory role of endogenous estrogens during male adolescence. J Clin Endocrinol Metab 1994;79:513-518.
32. Cutler GB Jr: The role of estrogen in bone growth and maturation during childhood and adolescence. J Steroid Biochem Mol Biol 1997;61:141-144.
33. Hero M, Wickman S, Dunkel L: Treatment with the aromatase inhibitor letrozole during adolescence increases near-final height in boys with constitutional delay of puberty. Clin Endocrinol (Oxf) 2006;64:510-513
34. Leschek EW, Rose SR, Yanovski JA, Troendle JF, Quigley CA, Chipman JJ, Crowe BJ, Ross JL, Cassorla FG, Blum WF, Cutler GB Jr, Baron J: Effect of growth hormone treatment on adult height in peripubertal children with idiopathic short stature: a randomized, double-blind, placebo-controlled trial. J Clin Endocrinol Metab 2004;89:3140-3148.
35. Yanovski JA, Rose SR, Municchi G, Pescovitz OH, Hill SC, Cassorla FG, Cutler GB Jr: Treatment with a luteinizing hormone-releasing hormone agonist in adolescents with short stature. N Engl J Med 2003;348:908-917.
36. Wickman S, Kajantie E, Dunkel L: Effects of suppression of estrogen action by the p450 aromatase inhibitor letrozole on bone mineral density and bone turnover in pubertal boys. J Clin Endocrinol Metab 88:3785-3793.
37. Makitie O, Doria AS, Henriques F, Cole WG, Compeyrot S, Silverman E, Laxer R, Daneman A, Sochett EB: Radiographic vertebral morphology: a diagnostic tool in pediatric osteoporosis. J Pediatr 2005;146:395-401.
38. Helenius I, Remes V, Salminen S, Valta H, Makitie O, Holmberg C, Palmu P, Tervahartiala P, Sarna S, Helenius M, Peltonen J, Jalanko H: Incidence and predictors of fractures in children after solid organ transplantation: a 5-year prospective, population-based study. J Bone Miner Res 2006;21:380-387.
39. Wickman S, Saukkonen T, Dunkel L: The role of sex steroids in the regulation of insulin sensitivity and serum lipid concentrations during male puberty: a prospective study with a P450-aromatase inhibitor. Eur J Endocrinol 2002;146:339-346.
40. Hero M, Ankarberg-Lindgren C, Taskinen MR, Dunkel L: Blockade of ooestrogen biosynthesis in peripubertal boys: effects on lipid metabolism, insulin sensitivity, and body composition. Eur J Endocrinol 2006;155:453-460.
41. Tikkanen MJ, Nikkila EA: Regulation of hepatic lipase and serum lipoproteins by sex steroids. Am Heart J 1987;113:562-567.
42. Bottner A, Kratzsch J, Muller G, Kapellen TM, Bluher S, Keller E, Bluher M, Kiess W: Gender differences of adiponectin levels develop during the progression of puberty and are related to serum androgen levels. J Clin Endocrinol Metab 2004;89:4053-4061.
43. Mauras N, O'Brien KO, Klein KO, Hayes V: Estrogen suppression in males: metabolic effects. J Clin Endocrinol Metab 2000;85:2370-2377.
44. Geisler J, Haynes B, Anker G, Dowsett M, Lonning PE: Influence of letrozole and anastrozole on total body aromatization and plasma estrogen levels in postmenopausal breast cancer patients evaluated in a randomized, cross-over study. J Clin Oncol 2002;20:751-757.
45. Zmunda JM, Thompson PD, Dickenson R, Bausserman LL: Testosterone decreases lipoprotein(a) in men. Am J Cardiol 1996;77:1244-1247.
46. Danesh J, Collins R, Peto R: Lipoprotein(a) and coronary heart disease. Meta-analysis of prospective studies. Circulation 2000;102:1082-1085.
47. Moran A, Jacobs DR Jr, Steinberger J, Hong CP, Prineas R, Luepker R, Sinaiko AR: Insulin resistance during puberty: results from clamp studies in 357 children. Diabetes 1999;48:2039-2044.
48. Hampson E: Estrogen-related variations in human spatial and articulatory-motor skills. Psychoneuroendocrinology 1990;15:97-111.
49. Shilling V, Jenkins V, Fallowfield L, Howell T: The effects of hormone therapy on cognition in breast cancer. J Steroid Biochem Mol Biol 2003;86:405-412.
50. Cherrier MM, Matsumoto AM, Amory JK, Ahmed S, Bremner W, Peskind ER, Raskind MA, Johnson M, Craft S: The role of aromatization in testosterone supplementation: effects on cognition in older men. Neurology 2005;64:290-296.
51. Couse JF, Korach KS: Estrogen receptor null mice: what have we learned and where will they lead us? Endocr Rev 1999;20:358-417.
52. Krege JH, Hodgin JB, Couse JF, Enmark E, Warner M, Mahler JF, Sar M, Korach KS, Gustafsson JA, Smithies O: Generation and reproductive phenotypes of mice lacking estrogen receptor beta. Proc Natl Acad Sci USA 1998;95:15677-15682.
53. Robertson KM, O'Donnell L, Jones ME, Meachem SJ, Boon WC, Fisher CR, Graves KH, McLachlan RI, Simpson ER: Impairment of spermatogenesis in mice lacking a functional aromatase (cyp 19) gene. Proc Natl Acad Sci USA 1999;96:7986-7991.
54. Shetty G, Krishnamurthy H, Krishnamurthy HN, Bhatnagar S, Moudgal RN: Effect of estrogen deprivation on the reproductive physiology of male and female primates. J Steroid Biochem Mol Biol 1997;61:157-166.
55. Raman JD, Schlegel PN: Aromatase inhibitors for male infertility. J Urol 2002;167:624-629.
56. Mauras N, Bell J, Snow BG, Winslow KL: Sperm analysis in growth hormone-deficient adolescents previously treated with an aromatase inhibitor: comparison with normal controls. Fertil Steril 2005;84:239-242.